1-(6-Chloropyridazin-3-yl)piperidine-4-carboxylic acid

Catalog No.: 
ACLZBG421
CAS No.: 
339276-36-7
Molecular Formula: 
C10H12ClN3O2
Molecular Weight: 
241.68
1-(6-Chloropyridazin-3-yl)piperidine-4-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$56.00In stockInquiry
250mg95%$79.00In stockInquiry
1g95%$240.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(6-Chloropyridazin-3-yl)piperidine-4-carboxylic acid
IUPAC Name1-(6-chloropyridazin-3-yl)piperidine-4-carboxylic acid
MDL No.MFCD00664523
Molecular FormulaC10H12ClN3O2
Molecular Weight241.68
SMILESO=C(C1CCN(C2=NN=C(Cl)C=C2)CC1)O
InChI KeyDLQSEGIGDCETIS-UHFFFAOYSA-N
Synonym1-(6-CHLORO-3-PYRIDAZINYL)-4-PIPERIDINECARBOXYLIC ACID;1-(6-CHLOROPYRIDAZIN-3-YL)PIPERIDINE-4-CARBOXYLIC ACID;4-Piperidinecarboxylic acid, 1-(6-chloro-3-pyridazinyl)-
CAS No.339276-36-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACLZBG421 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLZBG421 route product structure diagram
    ACLZBG421339276-36-7In Stock
Inquiry

2. ACLZBG421 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLZBG421 route product structure diagram
    ACLZBG421339276-36-7In Stock
Inquiry

3. ACLZBG421 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLZBG421 route product structure diagram
    ACLZBG421339276-36-7In Stock
Inquiry

Comments (0)